Sexual transmission of HCV not seen in US women's HIV cohort

Michael Carter, Michael Carter
Published: 22 October 2003

A large US study has found that very few HIV-positive women become coinfected with hepatitis C virus (HCV) after an HIV diagnosis. Writing in the November 15th edition of Clinical Infectious Disease, which is now available online, investigators also note that past or current drug use is by far the strongest risk factor for infection with HCV, and that a sizeable minority of women who do contract HCV will naturally clear the virus. Although several recent studies involving HIV-positive gay men have suggested that HCV may be more readily transmitted during sex than previous thought, the US investigators found no evidence of the sexual transmission of HCV in the women enrolled in their study.

This retrospective study involved a total of 2059 HIV-positive women and 569 HIV-negative women who were enrolled in the Women’s Interagency HIV Study (WIHS). Stored blood samples obtained between 1994 – 99 were used for the study. On entry into the study women were tested for HCV and answered questions about drug use and their sexual behaviour. Follow-up was every six months.

At baseline, HCV antibody tests were negative for 55% of the HIV-positive women and 69% of the HIV-negative women.

Over a mean of 3.5 years of follow-up, a total of 22 (1.5%) women seroconverted for HCV. However, the weakness of HCV antibody response in eight women led the investigators to conclude that only 14 of the women were true incident HCV infections (ten HIV-positive, four HIV-negative).

These 14 cases were used to calculate the incidence of HCV infection in the study population. Amongst HIV-positive women, the incident rate was 2.7 per 1000 person years, and amongst HIV-negative women 3.3 cases per 1000 person years. The difference in incidence between HIV-positive and HIV-negative women was not statistically significant (p=0.76).

Women with a history of drug use of any kind, either during the study period or before enrollment, were significantly more likely to become infected with HCV than women who never used drugs (5.3 cases per 1000 person years versus 0.7 cases, p=0.01).

When the investigators looked at the drug use patterns of the 14 women with new HCV infection they found that six had a history of crack, cocaine or heroin use during the study period, and that six other women reported the use of these drugs before entry to the study. In total 86% of women who acquired HCV reported current or prior drug use, compared to 22% of the 1517 HCV-negative women at enrollment (p<0.01).

Birth in Puerto Rico was the only other significant risk factor for HCV infection(p=0.02).

Of particular note, the investigators found no association between acute HCV infection and the total life-time number of sexual partners, frequency of condom use, or history of sexually transmitted infection.

The CD4 cell counts of women who contracted HCV were comparable to those who remained HCV free (433 cells/mm3 versus 385 cells/mm3. There were no readily identifiable trends in the HIV viral loads of women after their infection with HCV, although in the HAART treated women HIV viral load did decline by an average of 50,000 copies/mL to an average of 6000 copies/mL, which the investigators attribute to the effects of anti-HIV therapy.

HCV viraemia was detected in 12 of the women, with HCV viral load measuring from <42, 000 copies/mL to 19,000 million copies/mL. Eight of the twelve women were infected with HCV genotype 1a and three with genotype 1b. In total, five women (42%) lost measurable HCV during the study period.

The investigators comment “the incident rate of HCV infection in this large group of women with or at risk of HIV-1 infection was low.” However, given the high risk of HCV infection from injecting drug use and the high prevalence of HCV infection in the study cohort at baseline, the investigators add, “it is likely that those in the WIHS cohort at highest risk of HCV acquisition had already acquired infection before enrollment.”

Investigators also note that 42% of women who became viraemic for HCV appeared to clear infection. This is substantially higher than the current estimate that 15% of infected individuals will not develop chronic infection. They note, however, that the women in this study who cleared the infection had low HCV viral peaks.

”Conclusions about HCV acquisition and acute infection are limited by the relatively few cases of seroconversion detected”, caution the investigators. Nevertheless, they suggest that some important observations should be noted, in particular that acute HCV was almost exclusively seen in women with current or past drug use. Furthermore, an antibody response may not develop for some time in some HCV-exposed individuals. In addition, many HCV infected individuals will clear the infection, particularly if they are not immunosuppressed, and will do so soon after infection.

Further information on this website

Hepatitis C - overview

The liver and hepatitis C - factsheets

HIV and hepatitis - booklet in the information for HIV-positive people series (pdf)

Fisting, drug use, syphilis; risk factors for hepatitis C transmission in HIV-positive gay men - news story


Augenbraun M et al. Incident hepatitis C virus in women with human immunodeficiency virus infection. Clinical Infectious Diseases 37 (on-line edition), 2003.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.